Early Parkinson's Disease Monotherapy With CVN424

Summary

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Timeline

Start

2023-09-11

Primary completion

2025-01-30

Completion

2025-02-13

Outcome

Missed primary endpoint

registry analysis (other test); CVN424 150 mg vs Placebo; p = 0.7507; Least Square Mean Difference -0.73 (95% CI -5.3 to 3.8) NCT06006247 ↗

Drugs

Indications